Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 15,545 as of Thursday, July 25, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,346 issues advancing vs. 1,602 declining with 83 unchanged. The Health Care sector currently sits up 0.5% versus the S&P 500, which is unchanged. Top gainers within the sector include Boston Scientific ( BSX), up 11.6%, Vertex Pharmaceuticals ( VRTX), up 2.5%, Amgen ( AMGN), up 1.9%, Celgene Corporation ( CELG), up 1.7% and Biogen Idec ( BIIB), up 1.4%. On the negative front, top decliners within the sector include Humana ( HUM), down 2.3%, Intuitive Surgical ( ISRG), down 2.5%, WellPoint ( WLP), down 1.7%, Bristol-Myers Squibb Company ( BMY), down 1.1% and Baxter International ( BAX), down 1.1%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Alkermes ( ALKS) is one of the companies pushing the Health Care sector higher today. As of noon trading, Alkermes is up $1.51 (5.2%) to $30.68 on average volume. Thus far, 903,772 shares of Alkermes exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $29.00-$31.00 after having opened the day at $29.24 as compared to the previous trading day's close of $29.17. Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. Alkermes has a market cap of $4.0 billion and is part of the drugs industry. Shares are up 59.3% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Alkermes a buy, 1 analyst rates it a sell, and 1 rates it a hold. TheStreet Ratings rates Alkermes as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Alkermes Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.